Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

Groundwork BioAg and Sustainable Travel International Partner to Offer Carbon Dioxide Removal Credits for Tourism

Groundwork BioAg

Groundwork BioAg ®, the world’s largest producer of mycorrhizal inoculants, announced a new partnership with Sustainable Travel International, a global leader in sustainable tourism solutions, to offer travelers and businesses access to premium carbon dioxide removal (CDR) credits, based on the application of mycorrhizal fungi in cropland. Mycorrhizal inoculants are applied in agricultural soils to improve crop yields, save fertilizer, reduce plant stress, and improve soil health – but at the same time, these microbial products act as a natural pathway to permanently sequester carbon. This partnership aligns with Sustainable Travel International’s mission to provide programs that help travelers, businesses and destinations protect the environment, preserve cultural heritage and promote economic development. Groundwork BioAg's Rootella Carbon™ program offers high-integrity, high-volume, durable carbon credits that are independently certified and approved, providing a reliable solution for organizations seeking to meet their net-zero pledges responsibly. "By adding Rootella Carbon to our Climate Impact Portfolio, we reaffirm our commitment to promote holistic environmental stewardship so our members can visit – and protect – the places they love,” said Paloma Zapata, CEO of Sustainable Travel International. “This innovative, nature-based solution aligns with our mission to help the travel industry address its carbon liability while directly improving soil health around the world.” Sustainable Travel International’s Climate Impact Portfolio includes a wide variety of projects in different locations that generate carbon credits as they reduce or remove emissions. The portfolio includes a mix of high-quality forestry, clean/efficient energy, blue/teal carbon, and innovative climate tech projects. The demand for high-quality carbon credits is growing rapidly, with two-thirds of the world's largest companies with net-zero targets using carbon offsets to help meet their climate goals. Rootella Carbon credits stand out among durable CDR credits as a scalable solution that not only sequesters carbon in the soil but also improves crop yields, reduces chemical fertilizer use, mitigates plant stress and supports regenerative agricultural practices. Dan Grotsky, co-founder and chief growth officer of Groundwork BioAg, said, "This collaboration not only validates the effectiveness of our Rootella Carbon program but also demonstrates the travel industry's commitment to sustainable practices. Together, we are paving the way for significant carbon sequestration by enabling travelers and rewarding farmers around the world – while contributing to a healthier planet." Rooted in Groundwork BioAg’s history of helping growers improve the productivity and profitability of their farms, this partnership now gives travelers the opportunity to directly support farmers for their land stewardship while reducing their own carbon footprint. Currently under validation within the Verra VM0042 v2.0 protocol, Rootella Carbon offers farmers the opportunity to earn up to 70% of net proceeds from carbon credit sales, making it an attractive option for growers looking to diversify their income streams. This innovative approach unlocks compensation for regenerative growers who would otherwise be ineligible for carbon credits, while incentivizing conventional farmers to adopt regenerative practices. For more information about Groundwork BioAg and the Rootella Carbon program, visit GroundworkBioAg.com. About Groundwork BioAg Groundwork BioAg, a leading bioagriculture company, produces cost-effective mycorrhizal inoculants at scale to tackle food insecurity and climate change. Groundwork BioAg’s nature-based carbon dioxide removal solution leverages mycorrhizae as carbon’s main pathway into the soil and is supercharging permanent carbon sequestration on millions of hectares of commercial and regenerative farms globally. We envision the world’s cropland regenerating with mycorrhizae and every farmer benefiting from higher yields, healthier soils, fertilizer reduction, and verifiable, premium carbon credit revenue – without altering cultivation practices. Nature’s most potent carbon removal solution is now in every farmer’s hands. For more information, visit groundworkbioag.com or groundworkbioag.com/rootella-carbon. Contact Details AgTech PR for Groundwork BioAg Jennifer Goldston jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

January 22, 2025 10:32 AM Central Standard Time

Cortland Biomedical Secures FDA Registration, Expanding Role as a Trusted Contract Manufacturer for Medical Device OEMs

Cortland Biomedical

Cortland Biomedical, a full-service biomedical textile product development partner that provides access to a full spectrum of global engineering, design, and manufacturing capabilities, is proud to announce its FDA registration, marking a significant milestone in the company’s evolution. This new designation positions Cortland Biomedical as a full-service contract manufacturer and reinforces the company’s unwavering commitment to delivering the highest standards of quality, compliance, and service to its medical device customers. As an FDA-registered contract manufacturer, Cortland Biomedical will better support its clients in highly regulated markets, particularly in the orthopedic sector, where precision and reliability are critical. The FDA registration, partnered with ISO 13486:2016 compliance, ensures that Cortland Biomedical operates under a robust Quality Management System (QMS) that meets stringent regulatory requirements, offering its customers peace of mind in the safety and performance of their devices. “FDA registration is a game-changer for Cortland Biomedical and our customers,” said Tara Yunkunis, Senior Business Development Manager, Cortland Biomedical. “This milestone underscores our dedication to maintaining world-class quality systems and compliance practices. As a contract manufacturer, we can now take a more active role in helping our customers bring innovative medical devices to market faster and with greater confidence.” With extensive expertise in the design and production of advanced biomedical textiles, Cortland Biomedical specializes in creating tailored solutions for a range of applications, including orthopedics, sports medicine, cardiovascular, robotic surgery, general surgery, and others. This expanded capability allows it to now partner with OEMs from initial concept through full-scale manufacturing, providing a seamless, forward-integrated approach to medical device development. For more information about Cortland Biomedical and its expanded capabilities as an FDA-registered contract manufacturer, visit cortlandbiomedical.com or come see the team in booth 2127 at the upcoming MD&M West show in Anaheim, CA. Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical's unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers' complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

January 22, 2025 10:00 AM Eastern Standard Time

How Monogram’s (NASDAQ: MGRM) Dynamic Approach To Robotics Could Help Reshape the Future Of Orthopedics

Benzinga

By Meg Flippin Benzinga Robots are becoming increasingly more common in the operating room, but just how automated are they? Monogram Orthopedics Inc. (NASDAQ: MGRM) would argue we have a long way to go before the full potential of robotic technology is fully tapped. The proliferation of robotics and increasing utilization is, at this point, likely a foregone conclusion. After all, some estimates predict that 50% of all knee procedures will be robotic by 2027, up from 11% in 2019. Yet despite the proliferation of AI and fully autonomous robotics in nearly every aspect of daily life, the surgical equipment currently in use for common orthopedic procedures is still reliant on surgeon skill. Monogram’s mBôs robotic technology aims to increase automation and reduce reliance on user skills. As a pioneer in autonomous saw-based cutting, the company has applied decades of robotics experience to amass an extensive portfolio of innovation, including some 23 patent applications in process. The majority of procedures done today combine manual surgery with robotics. The process can still rely heavily on surgeon skill to safely execute the surgery. Monogram’s mBôs aims to minimize direct surgeon contact with the robot mounted tools and hopes to provide surgeons a more autonomous platform for precise surgical bone cuts based on preoperative planning. Monogram’s autonomous robotics platform captured the attention of investment bank Roth Capital Partners, which recently initiated coverage of the company, noting mBôs simplifies surgery as a likely direct challenge to the dominant players in the space. “While orthopedic surgeons remain characteristically conservative, the clinical case for robotics technology is building, and robotics are changing market dynamics,” according to an analyst report compiled by Roth Managing Director Jason Wittes. “We anticipate adoption surpassing 50% over the next five years, and thus see significant strategic value in emerging robotics platforms such as MGRM's mBôs that can challenge MAKO’s dominance.” In addition, Monogram reports its technology pipeline is robust. It plans to introduce mVision in the future, which could enable faster registration and further optimize surgical time compared to competitors. Combination Of Advanced Technologies To Deliver Results Monogram leverages AI and robotics to develop state-of-the-art robots that can assist surgeons with knee reconstruction and, in the future, other procedures like hips, shoulders, ankles and spine. Monogram’s robotic systems aim for precise virtual assessment of laxity values to determine the potential clinical impact of planned resections. Its technology enables surgeons to place implants virtually before cutting to assess the impact of various resections on knee laxity with a target to achieve submillimeter bone cuts. These tools could dramatically simplify the complexity of joint reconstruction in the future. Monogram hopes the mBôs automation could increase throughput and hopes to reduce clinical risk with a planned clinical study to validate. The goal is for the robot to be easy to use and to lower the learning curve for surgeons. With accurate robotics, precision machine cuts can help enable the use of press-fit implants, eliminating the need for cement. Unlike traditional implants, press-fit implants rely on the patient’s bone to hold the implant in place instead of relying on cement. Natural biologic fixation could reduce the risk of the implant becoming loose for younger active patients as the cement breaks down over time. Showing Off The Tech At HQ Monogram’s unique approach to robotics was on display during an analyst meeting and demo day held in 2024 at the company’s cadaver lab and headquarters in Austin, Texas. Monogram executives – including CEO Ben Sexson, Founder and Chief Medical Officer Dr. Douglas Unis, Chief Technology Officer Dr. Kamran Shamaei and Chief Financial Officer Noel Knape – were on hand along with other senior management team members to provide an overview of the company's progress in combining advanced machine vision, AI and next-generation robotics to improve surgeries and patient outcomes. “We were extremely impressed with the management team, including founder Doug Unis, and the successful product Demonstration of the mBôs Precision Robotic Surgical System in a world-class cadaver lab,” said Dallas Salazar, Doctor Group investor. “The hands-free, fully active system demonstrated to us the ease of use and simplicity that was operated by the founder’s 11-year-old daughter giving more confidence of commercialization and acceptance in the orthopedic robotics community once approved. We believe there is clearly a disruptor in this space that is now bringing a product solution architecture to enable patient-optimized orthopedic implants at scale utilizing artificial intelligence and next-generation robotics.” Market Direction The company believes that the future of the market for robotics is bright. With continued robotic adoption driven by patient outcomes and healthcare providers, it believes robotics are likely to become increasingly autonomous. Given the advancements made in AI and robotics, the systems in place today may still be relatively constrained by a reliance on the precision of individual surgeons. The full potential of robotics could be realized across myriad industries. With the anticipated growth in surgical procedures and critical patient and healthcare business outcomes at stake, coupled with a declining number of orthopedic surgeons, automation could be an answer to the growing demand. Monogram aims to introduce an approach to enabling true automated robotic precision that has the potential to transform the way surgeons around the world perform knee replacements and other orthopedic procedures. Featured photo by SOMKID THONGDEE on Shutterstock. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 22, 2025 08:45 AM Eastern Standard Time

Image

News Release

Salignostics Advances Saliva-Based HIV Testing with Successful Clinical Trial in Ethiopia

Salignostics

Salignostics, a leader in saliva-based diagnostic innovation, proudly announces the successful completion of a clinical trial in Ethiopia for its groundbreaking saliva-based HIV rapid test. This major milestone brings Salignostics closer to providing a transformative solution for HIV testing, particularly in areas with limited access to healthcare infrastructure. The trial, conducted in November 2024, evaluated 50 saliva samples from individuals diagnosed with HIV alongside 50 samples from healthy participants. The results demonstrated exceptional accuracy, with sensitivity exceeding 90% and specificity surpassing 98%. These findings underscore the reliability of saliva as a diagnostic medium and highlight its potential to address critical healthcare challenges worldwide. Accurate, accessible HIV testing is vital for early detection and treatment, especially in underserved regions. Salignostics’ saliva-based test eliminates the need for blood draws and specialized equipment, offering a cost-effective and non-invasive alternative that can be deployed in homes, clinics, or community health settings. This innovation not only reduces barriers to testing but also empowers individuals to take control of their health with privacy and convenience. “This successful trial highlights the value of saliva as a diagnostic medium,” said Dr. Guy Krief, Co-founder and Deputy CEO of Salignostics. “By leveraging our technology, we aim to complement existing HIV testing methods and provide a reliable, accessible solution that meets the needs of diverse communities worldwide.” The global HIV diagnostics market is rapidly expanding, driven by increasing demand for decentralized and user-friendly solutions. The market is projected to reach $3.88 billion by 2021, with forecasts of further growth to over $7 billion by 2034 at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2034. Building on its success with saliva-based diagnostics, Salignostics continues to expand its portfolio. The company has a proven track record, including CE, UKCA, and TGA certifications for its Salistick pregnancy test, which has achieved over 500,000 units sold and ordered across markets such as the UK and Israel. Salignostics’ development pipeline also includes applications for oral cancer, respiratory conditions, and sexually transmitted infections, further demonstrating the versatility of saliva as a diagnostic tool. For Salignostics, the successful Ethiopian trial is a significant step forward in transforming global healthcare. By providing accurate and accessible HIV testing, the company is addressing critical gaps in public health while reinforcing its commitment to innovation and quality in diagnostics. About Salignostics Founded in 2017 in Jerusalem, Salignostics is a global leader in saliva-based diagnostics. The company’s proprietary technology has been successfully commercialized, with its Salistick pregnancy test achieving over 500,000 units sold and ordered in markets such as the UK and Israel. Now approved by CE, UKCA, and TGA, Salignostics is actively expanding its portfolio of innovative, user-friendly diagnostic solutions. For more information about Salignostics and its groundbreaking saliva-based diagnostics, visit www.salignostics.com Founded in 2017 in Jerusalem, Salignostics is a global leader in saliva-based diagnostics. The company's proprietary technology has been successfully commercialized, with its Salistick pregnancy test achieving over 500,000 units sold and ordered in markets such as the UK and Israel. Now approved by CE, UKCA, and TGA, Salignostics is actively expanding its portfolio of innovative, user-friendly diagnostic solutions. For more information about Salignostics and its groundbreaking saliva-based diagnostics, visit www.salignostics.com Contact Details Salignostics Guy Krief | Co-founder and Deputy CEO, Salignostics guykrief@salignostics.com Company Website https://www.salignostics.com/

January 21, 2025 05:15 PM Eastern Standard Time

Flash Earns HITRUST Certification, a First in Parking Technology

Flash

Flash, the leading AI-powered parking technology provider, today announced it has achieved HITRUST Certification for its PARCS and Valet solutions, the first and only parking technology provider to earn the distinction. The achievement confirms Flash’s data security practices meet the highest standards trusted by 81 percent of U.S. hospitals and health systems. Flash's HITRUST-certified PARCS and Valet solutions align its security frameworks with those of its healthcare clients and reduce their implementation complexity and risk. The certification also gives assurance to patients, visitors, physicians and staff that their information is safe from the moment they enter the parking facility. “We have a track record of setting new standards in parking," said Flash CEO Dan Sharplin. “Our focus on reimagining the parking experience calls for putting security front and center, within and beyond healthcare. We’re also committed to a great experience for operators and owners, and this certification allows us to carry the technical burden of compliance on their behalf.” Flash PARCS and Valet solutions have earned the trust of the country’s largest medical district and from healthcare systems in major metros nationwide, including Atlanta, Boston, Chicago, Denver, Houston, New York City, Orange County, Phoenix, Pittsburgh and San Diego. Flash’s industry-leading parking technology has also earned designation as a Level 1 Service Provider by the Payment Card Industry (PCI) Data Security Standards (DSS), which it has maintained for 11 consecutive years. Its cloud-based platform can process over 500 million transactions yearly in a secure environment that limits the risk of data loss, disruption, or corruption. Operating entirely in the cloud also allows Flash to manage compliance for operators and owners, pushing security updates and routine system checks required by PCI and HITRUST standards over the air, which become operational within minutes. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use daily with garage, surface lot, event, and valet parking locations—connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress. The solution has arrived. Visit www.flashparking.com to learn more. Contact Details Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

January 21, 2025 10:00 AM Central Standard Time

IntusCare Announces Marcus Whitney as New Board Member, Strengthening Leadership and Expertise in Healthcare Innovation

IntusCare

IntusCare, a technology leader in the PACE market, today announced the addition of Marcus Whitney, founder and managing partner of Jumpstart Health Investors (JHI), to its Board of Directors. A healthcare venture capitalist, author, and thought leader, Whitney brings his extensive expertise in healthcare innovation and strategic investments and marks a significant step forward in the company’s commitment to improving healthcare outcomes for older adults through technology and services. As a founding partner of JHI, an early-stage healthcare venture capital firm, Whitney has been instrumental in driving investments that focus on high-impact healthcare solutions that address healthcare disparities and push for equitable access to care. Whitney’s approach emphasizes not use innovation but inclusivity – values that align with IntusCare’s mission to enhance PACE and value-based care (VBC) organizations. Whitney joins the board at IntusCare as the company continues to expand its technology platform, recently announcing a new EMR and practice management solution, CareHub, along with a risk adjustment system, IRIS, both uniquely designed specifically for PACE and VBC organizations. “Marcus’s visionary approach and expertise in healthcare innovation will enhance our approach at IntusCare as we continue to look for ways our technology and services will empower the healthcare providers we support,” said Robbie Felton, CEO at IntusCare. “His expertise will be invaluable as we continue to develop technology that enables healthcare providers to deliver more effective, compassionate care to underserved elderly populations.” “I am honored to serve on the board for IntusCare. The IntusCare team is leading the industry in redefining care for a critical population,” said Whitney. “I look forward to contributing to their mission and the bright future ahead.” In addition to his role at JHI, Whitney is a best-selling author of “Create and Orchestrate,” about claiming your creative power through entrepreneurship. Whitney is an Aspen Health Innovators Fellow and serves on multiple boards that support healthcare and the arts; this includes the Healthcare Financial Management Association National Board. He is also co-founder and minority owner of the Major League Soccer team, Nashville Soccer Club. Whitney competes in Jiu Jitsu as an International Brazilian Jiu-Jitsu Federation (IBJJF) World Master Champion. For more information about IntusCare’s software and services or to schedule a demo or consultation, reach out through IntusCare’s website. About IntusCare ‍ IntusCare develops innovative predictive analytics platforms aimed at improving geriatric care outcomes. Founded in 2019 by Brown University undergraduate students, IntusCare empowers geriatric care providers to deliver more effective patient management and treatment for dual-eligible seniors – some of the most socially vulnerable and clinically complex individuals in the U.S. healthcare system. Visit our website to learn more intuscare.com. Contact Details SVM PR & Marketing Alison Matthiessen +1 401-490-9700 intuscare@svmpr.com Company Website https://intuscare.com/

January 21, 2025 10:00 AM Eastern Standard Time

Soligenix Targets Psoriasis With New Therapy

Benzinga

By Kyle Anthony, Benzinga The skin is the largest organ in the human body. Its softness allows for movement and flexibility, yet it is also durable enough to typically resist breaking or tearing. As one of the body’s more versatile organs, it serves multiple functions, such as being the first line of defense against bacteria and other organisms. However, the skin has another vital role as an indicator of good health; if someone is sick, it often shows in their skin. Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases and areas of unmet medical need, is utilizing its pharmaceutical expertise to tackle psoriasis, an autoimmune skin condition that causes itchiness and discomfort. Psoriasis Explained Psoriasis is an autoimmune condition that causes skin inflammation, exacerbated by T-cells of the adaptive immune system (autoimmune response). Symptoms include thick areas of discolored skin covered with scales called plaques. Psoriasis is a chronic skin condition that can flare up unexpectedly. Presently, there is no cure for this condition. According to the National Psoriasis Foundation, approximately 125 million people worldwide suffer from this condition, with more than 8 million of them being in the U.S. Psoriasis has several types, each manifesting on the body and affecting individuals differently. Plaque psoriasis is the most common type; about 80% to 90% of people with psoriasis have plaque psoriasis. Most psoriasis patients have mild or moderate forms of the disease. The former means less than 3% of the body surface area is involved, while the latter usually involves between 3% and 10%. Disease involving more than 10% of body surface area is generally classified as severe. The implications of having psoriasis are not purely aesthetic, as it can decrease a patient’s quality of life including itchiness, dry, cracked skin that can be susceptible to infection and potentially anxiety relating to appearance. Psoriasis can also be associated with cardiovascular, arthritic and metabolic diseases, as well as anxiety, depression and suicide. Psoriasis itself can evolve into chronic inflammatory arthritis called psoriatic arthritis. In addition, individuals with severe psoriasis can have an increased risk of lymphoma, like cutaneous T-cell lymphoma. Soligenix’s Treatment Of Psoriasis Generally, treatment for psoriasis is predicated on its severity. The primary objective in treating psoriasis is to reduce the rate at which skin cells grow and divide and to remove the scales. Treatments can be divided into topical treatments, light therapy (phototherapy or photodynamic therapy) and systemic (oral or injected) medications. Soligenix’s product offering for treating psoriasis is SGX302. This treatment utilizes photodynamic light therapy and synthetic hypericin to treat mild-to-moderate psoriasis. Hypericin is renowned for its antimicrobial properties, including activity against bacteria, fungi and viruses. SGX302’s treatment methodology involves applying an ointment to the affected areas and utilizing a visible light to activate it. Soligenix reports that synthetic hypericin tends to accumulate in T-cells. When synthetic hypericin is activated, it creates oxygen radicals, which subsequently kill the targeted T-cells, Soligenix says. Soligenix reports that clinical studies with SGX302 have found it safe and efficacious in treating the disease. The press release regarding the phase 2a study noted that all patients tolerated SGX302 therapy well, and no drug-related adverse events were identified. Furthermore, the Psoriasis Activity and Severity Index (PASI) score, another well-characterized measure of treatment success, had a mean drop of approximately 50% over the 18-week treatment for patients in cohort 2. Regarding the success of their clinical studies and the learnings gathered, Christopher J. Schaber, PhD, president and CEO of Soligenix, has stated, "We are pleased with the preliminary findings from our ongoing Phase 2a trial. Current estimates show as many as 60-125 million people worldwide living with the condition, with a global treatment market valued at approximately $15 billion in 2020 and projected to reach as much as $40 billion by 2027. The success of HyBryte™ in targeting malignant T-cells during CTCL clinical trials is a promising indicator of the ability of SGX302 to provide a much-needed approach for the treatment of mild-to-moderate psoriasis, also caused by dysregulated T-cells." Soligenix says it is making material and meaningful progress in treating psoriasis. As the firm progresses in tackling psoriasis and other rare diseases, it hopes to establish a distinct value proposition in the market. For more information on Soligenix's recent stock performance, click here. Featured photo by Louis Reed on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 17, 2025 08:30 AM Eastern Standard Time

Image

News Release

IntusCare Increases Total Funding to Over $27M through Strategic Follow-On Financing

Intus Care

IntusCare, a leading provider of predictive analytics solutions for geriatric care, today announced it has raised $11.5 million in a strategic follow-on financing round. This latest investment brings the company's total funding to over $27 million, underscoring the strong market positioning of IntusCare's innovative approach to improving care outcomes for complex senior populations. The investment round was led by Deerfield Management, with participation from Citi Impact Fund, Jumpstart Nova, and other existing IntusCare investors. This infusion of capital will fuel the launch of CareHub, a comprehensive care management platform, and support the expansion of IntusCare's existing suite of Revenue Integrity, Population Health, and Utilization Management solutions. Additionally, the company plans to accelerate its artificial intelligence research, aiming to enhance user experiences for healthcare providers and staff. Revolutionizing Care Management with CareHub CareHub is designed to accelerate the growth and success of Programs of All-Inclusive Care for the Elderly (PACE) and other value-based care models. The platform addresses critical needs in the PACE community and beyond, including: Reducing documentation and administrative burden Integrating or replacing disparate, non-interoperable data systems Driving actionable insights for interdisciplinary care teams to improve medical utilization "With CareHub, we're taking a significant step forward in our mission to create the platform that organizations use to deliver the right care, at the right time, every day for older adults with complex needs," said Robbie Felton, CEO and co-founder of IntusCare. "This product is the result of our deep understanding of the unique challenges faced by PACE programs and other value-based care systems with technology, interoperability, and managing complex Medicare and Medicaid populations." Expanding Beyond PACE While initially focused on PACE programs, IntusCare is strategically positioned to expand its product suite to serve Accountable Care Organizations (ACOs) and Special Needs Plans (SNPs). The company's solutions are particularly valuable for organizations taking on risk in complex Medicare and Medicaid populations. "The support from Deerfield Management and our other investors validates our customer-centric approach and enables us to accelerate our growth within the PACE space and into new markets," said Evan Jackson, COO and co-founder of IntusCare. "We're excited to bring our expertise in data interoperability, workflow optimization, and patient-focused care to a wider range of value-based care providers." Driving Innovation in Value-Based Care IntusCare's latest funding round will also support the expansion of its marketing function and the continued development of its core products. The company remains committed to driving innovation in the value-based care space, with a particular focus on improving outcomes for vulnerable senior populations. Ryan Alam, Senior Vice President of the Citi Impact Fund, emphasized the transformative potential of IntusCare’s work: “The PACE ecosystem has shown strong potential for improving outcomes for seniors with complex needs while allowing them to age in place. Currently, providers within these systems lack innovative technology to empower their workflows. IntusCare is working to address these technological shortcomings through a next-generation administrative, financial, and clinical software to support these models and the incredible care they offer to our most vulnerable population. We are thrilled to support IntusCare and deeply believe in their mission of expanding the reach of high-quality care.” Dr. Julian Harris, Operating Partner at Deerfield Management, added, "IntusCare continues to impress us with their innovative approach to solving critical technology and service problems in the PACE market and beyond. We believe their disruptive, AI-forward technology will play a vital role in revolutionizing the performance of interdisciplinary teams in the PACE, ACO, and Medicare SNP markets." For more information about IntusCare and its solutions, visit www.intuscare.com. About IntusCare IntusCare develops innovative predictive analytics platforms aimed at improving geriatric care outcomes. Founded in 2019 by Brown University undergraduate students, IntusCare empowers geriatric care providers to deliver more effective patient management and treatment for dual-eligible seniors - some of the most socially vulnerable and clinically complex individuals in the U.S. healthcare system. Learn more at intuscare.com. Contact Details SVM Public Relations Alison Matthiessen +1 401-490-9700 intuscare@svmpr.com Company Website https://www.intuscare.com/

January 16, 2025 10:00 AM Eastern Standard Time

U.S. surpassed 48,000 organ transplants in 2024

United Network for Organ Sharing

Today, the United Network for Organ Sharing (UNOS) announced that 48,149 organ transplants were performed in 2024, according to data from the Organ Procurement and Transplantation Network (OPTN). This is the first time the United States has ever performed more than 48,000 organ transplants in one year and represents a critical step in the nationwide effort to increase the number of lifesaving organ transplants while improving the system. On average, the U.S. performed 132 transplants a day in 2024. This lifesaving work was made possible thanks to the selfless gifts of life provided by 16,988 deceased donors and 7,030 living donors, as well as the support provided by so many donor families and the expertise of medical professionals across the country. “Each transplant represents an individual, a family, a story, and a life saved or improved,” said UNOS CEO Maureen McBride, Ph.D. “Each transplant also represents a selfless decision made by a grieving family or an inspired living donor, and it is incumbent upon us to honor each and every one of those irreplaceable gifts. That means working together to enact substantive reforms that increase the total number of transplants and the number of recovered donor organs ultimately transplanted.” UNOS continues to engage with Congress and other stakeholders and advocate for pragmatic policy changes that would benefit patients in need of transplants, which McBride outlined in a letter sent to the House Energy and Commerce Committee in December 2024 and was signed by nearly 70 donation and transplant professionals. These proposals, which require Congressional action, include: Mandating automated donor referrals to improve information sharing and ensure organ procurement organizations are alerted to every potential organ donor quickly and efficiently. Mandating in-cabin airline transportation for organs to drastically reduce the likelihood that lifesaving organs are damaged, lost or delayed in transit. Implementing a national, centralized, system-wide tracking system for unaccompanied organs to reduce delays, provide surgical teams with critical travel information, and produce data to drive additional improvements. Incentivizing transplant hospitals to accept harder-to-place organs by compensating them at a higher rate through Medicare when they transplant more medically complex kidneys. The data suggests this change could prevent an estimated 4,000 deaths. Taken together, this slate of reforms advanced by UNOS could result in a marked increase in both donor referrals and organ donors, a reduction in the number of organs that are not ultimately transplanted, and even more patients receiving the gift of life. “We are humbled that our community’s efforts and the generosity of so many across the country has resulted in over 48,000 transplants in a single year, but there is more work to do, and we cannot be satisfied with the status quo,” McBride said. “We will continue our work to strengthen the system as long as there are patients waiting for a transplant.” To learn more about UNOS’ recommendations, see UNOS’ Action Agenda. About UNOS The United Network for Organ Sharing (UNOS) is a nonprofit organization that serves the organ donation and transplant system and broader public health community through its work developing new technologies and initiatives, conducting data-driven research and analysis, providing expert consulting services, advocating for patients, and being a leader in bringing communities together to save lives. Contact Details United Network for Organ Sharing Anne Paschke anne.paschke@unos.org Company Website https://unos.org

January 15, 2025 12:41 PM Eastern Standard Time

Image

1 2 3 4 5 ... 299